Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Jerome Schartman
Observed names:
JEROME P. SCHARTMAN,
JEROME SCHARTMAN,
Jerome P Schartman,
Jerome P. Schartman,
Schartman, Jerome P.
Institutions:
Retina Associates of Kentucky,
Retina Associates of Florida,
Tennessee Retina
Observed institutions:
Pennsylvania State University,
Uniformed Services University of the Health Sciences,
Retina Associates of Kentucky,
Retina Associates of Florida,
Retina Research Foundation,
Tennessee Retina,
Albany Medical College
show all 7
OpenAlex ID:
A5060192865
Adverse Events After Intravitreal Infliximab (remicade)
2010
·
MONICA GIGANTI
, PAUL M. BEER
, et al.
·
Retina
·
133
B7 Requirements for Primary and Secondary Protein- and Polysaccharide-Specific Ig Isotype Responses to Streptococcus pneumoniae
2000
·
Zheng-Qi Wu
, Abdul Q Khan
, et al.
·
The Journal of Immunology
·
59
Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti–Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema
2018
·
Lee M. Jampol
, Adam R. Glassman
, et al.
·
Ophthalmology
·
44
Lapses in Care Among Patients Assigned to Ranibizumab for Proliferative Diabetic Retinopathy: A Post Hoc Analysis of a Randomized Clinical Trial
2021
·
Maureen G. Maguire
, Danni Liu
, et al.
·
JAMA Ophthalmology
·
33
Infliximab Stability After Reconstitution, Dilution, and Storage Under Refrigeration
2010
·
PAUL M. BEER
, SUSAN J. WONG
, et al.
·
Retina
·
19
Switching to brolucizumab: injection intervals and visual, anatomical and safety outcomes at 12 and 18 months in real-world eyes with neovascular age-related macular degeneration
2023
·
Joseph M. Coney
, Ryan Zubricky
, et al.
·
International Journal of Retina and Vitreous
·
18
PDF
Efficacy of Macular Hole Surgery in Patients with Idiopathic Macular Telangiectasia Type 2
2019
·
Alexander G. Miller
, Rohit Chandra
, et al.
·
Ophthalmology Retina
·
16
Intraocular Pressure–Related Events After Anti–Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Report 16 on a Secondary Analysis of a Randomized Clinical Trial
2021
·
Ahmad A. Aref
, Ingrid U. Scott
, et al.
·
JAMA Ophthalmology
·
14
Cost-Utility Comparison of Bevacizumab and Aflibercept in the Treatment of Central or Hemiretinal Vein Occlusion in the SCORE2 Trial
2023
·
Steven M. Kymes
, Neal L. Oden
, et al.
·
JAMA Ophthalmology
·
10
Baseline Characteristics and Outcomes After Anti–Vascular Endothelial Growth Factor Therapy for Macular Edema in Participants With Hemiretinal Vein Occlusion Compared With Participants With Central Retinal Vein Occlusion: Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Report 18
2022
·
Ingrid U. Scott
, Neal L. Oden
, et al.
·
JAMA Ophthalmology
·
7
Early surgical displacement of submacular hemorrhage without tissue plasminogen activator use: one-year outcomes
2023
·
Marwan Abdulaal
, Richard Donkor
, et al.
·
Canadian Journal of Ophthalmology
·
4
Frequency and Symptoms of Intravitreal Silicone Oil Droplets Following Becton Dickinson and Norm-Ject Bevacizumab Injections
2022
·
Chase W. Miller
, Matt A. Wilneff
, et al.
·
Ophthalmic surgery, lasers & imaging retina
·
3
One-Year and 18-Month Outcomes in nAMD Patient Eyes Switched to Brolucizumab Alone versus to Brolucizumab Alternating with Other Anti-VEGF Agents
2023
·
Joseph Coney
, Jasmyne McCoy
, et al.
·
Clinical ophthalmology
·
2
PDF
Pegaptanib octasodium for the treatment of diabetic macular edema
2011
·
Jerome P Schartman
, Joseph M Coney
, et al.
·
Expert Opinion on Pharmacotherapy
·
2
Incidence of Recurrent Choroidal Neovascularization Following Treatment with Pegcetacoplan for Geographic Atrophy in Exudative Age-Related Macular Degeneration Patients with Inactive Choroidal Neovascularization
2025
·
Ryan Zubricky
, Chase Miller
, et al.
·
Archives of Ophthalmology and Optometry
·
1
PDF
Surgical Outcomes and Patient Satisfaction in Vitrectomy for Vitreous Floaters
2019
·
Charles Pophal
, Rohit Chandra
, et al.
·
Investigative Ophthalmology & Visual Science
·
1
Fluocinolone acetonide (FAc) 0.2 mg intravitreal implant in the treatment of diabetic macular edema (DME)
2018
·
John Liu
, Joseph Coney
, et al.
·
Investigative Ophthalmology & Visual Science
·
1
The use of anti-vascular endothelial growth factor therapies in the macular telangiectasia associated with choroidal neovascularization.
2016
·
Musa Abdelaziz
, Mahdi Rostamizadeh
, et al.
·
Investigative Ophthalmology & Visual Science
·
1
First-Year Fellow Single Surgery Success Rate in Primary Rhegmatogenous Retinal Detachments
2025
·
Ryan Zubricky
, Harrison Sciulli
, et al.
·
Archives of Ophthalmology and Optometry
PDF
Frequency and symptoms of intravitreal silicone oil droplets following bevacizumab injections from BD insulin syringes
2020
·
David Miller
, Chase Miller
, et al.
·
Investigative Ophthalmology & Visual Science
Efficacy of the 0.19 mg Fluocinolone Acetonide (FAc) Implant (ILUVIEN®) in a Multiphysician, Single-practice Setting – The Cleveland Experience
2019
·
Daniel C Daroszewski
, Joseph Coney
, et al.
·
Investigative Ophthalmology & Visual Science
Efficacy of Ranibizumab in the Treatment of Diabetic Macular Edema Refractory to Bevacizumab
2013
·
Harrison Sciulli
, David Miller
, et al.
·
Investigative Ophthalmology & Visual Science
Intravitreal Ranibizumab for Treatment of Advanced Macular Dysfunction in Patients With Disciform Fibrosis Due to Exudative Age-Related Macular Degeneration: The SALVAGE Study
2009
·
Nicole Lemanski
, Jerome Schartman
, et al.
·
Investigative Ophthalmology & Visual Science
Angiographic Cystoid Macular Edema in Patients With Clinically Significant Diabetic Macular Edema
2006
·
Jerome Schartman
, David A. Quillen
, et al.
·
Investigative Ophthalmology & Visual Science
Intermittent disconjugate gaze
2006
·
Jerome Schartman
, Joel Weinstein
·
Hepatology
PDF
Show more works
View as search
Works count:
31
Citation count:
368
H-index:
9
I10-index:
9
Year
Topic
Type